1090154
Last Update Posted: 2021-12-14
Recruiting has ended
All Genders accepted | 18 Years-75 Years |
27 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Study of Cimzia for the Treatment of Ulcerative Colitis
The purpose of this study is to determine if Cimzia (certolizumab pegol) is an effective treatment for patients with Ulcerative colitis.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease which often results in significant morbidity as well as impairment in quality of life. Cimzia (certolizumab pegol), an inhibitor of tumor necrosis factor-alpha, is an effective treatment for Crohn's disease, a similar inflammatory bowel disease. The aims of this study are to determine if Cimzia is effective for both the induction and maintenance of response/remission for the patients with moderate to severe Ulcerative colitis.
Eligibility
Relevant conditions:
Ulcerative Colitis
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov